Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Drugmakers Call for More Flexible Templates for REMS

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:Drug Industry Daily

Parts of the FDA’s recently updated draft guidance on the content and formatting of REMS documents are overly prescriptive, stakeholders said in public comments to the agency. Source: Drug Industry…

Continue ReadingDrugmakers Call for More Flexible Templates for REMS

Biotechs Drool as VC Firm Andreessen Horowitz Doubles Down on the Life Sciences With New $450M Fund

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Biotechs are taking notice as a new pool of funding is being made available by venture capital Andreesen Horowitz. Source: BioSpace

Continue ReadingBiotechs Drool as VC Firm Andreessen Horowitz Doubles Down on the Life Sciences With New $450M Fund

Asklepios BioPharma Launches New Biotech Actus Therapeutics

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics. Source: BioSpace

Continue ReadingAsklepios BioPharma Launches New Biotech Actus Therapeutics

Suitors Line Up for Merck KGaA's $4.7B Consumer Health Biz

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Perrigo is expected to face competition from Swiss food giant Nestle and the private equity owners of German drug firm Stada. Source: BioSpace

Continue ReadingSuitors Line Up for Merck KGaA's $4.7B Consumer Health Biz

Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active…

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

The approval was based on data from the Phase 3 Oral Psoriatic Arthritis Trial (OPAL) clinical development program. Source: BioSpace

Continue ReadingPfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active…

These 2 Startups are Amgen's 2017 Golden Ticket Winners

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Amgen tapped two companies to receive its coveted 2017 Golden Ticket at LabCentral. Source: BioSpace

Continue ReadingThese 2 Startups are Amgen's 2017 Golden Ticket Winners

Novartis Oncology Head to Retire for Personal Reasons

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Bruno Strigini, the CEO of Novartis Oncology, plans to exit the company's Executive Committee by Dec. 31, 2017, and leave entirely in early 2018. Source: BioSpace

Continue ReadingNovartis Oncology Head to Retire for Personal Reasons

In the Nick of Time: Galapagos Nabs Co-Promotion Filgotinib Deal With Gilead

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Galapagos assumes 35% of the co-promotion efforts in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, and Luxembourg. Source: BioSpace

Continue ReadingIn the Nick of Time: Galapagos Nabs Co-Promotion Filgotinib Deal With Gilead

Bay Area Rigel's CFO to Exit, Effective Dec. 31, 2017

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Nelson Cabatuan, Rigel's vice president, finance will serve as the company's interim principal accounting officer. Source: BioSpace

Continue ReadingBay Area Rigel's CFO to Exit, Effective Dec. 31, 2017

How Amicus CEO Personally Appealed to FDA Head to Get Migalastat Back on Track

  • Post author:Sam
  • Post published:December 14, 2017
  • Post category:BioPharma

Industry analysts were shocked when in July the FDA reversed course on Amicus' Phase III treatment for Fabry disease. Source: BioSpace

Continue ReadingHow Amicus CEO Personally Appealed to FDA Head to Get Migalastat Back on Track
  • Go to the previous page
  • 1
  • …
  • 225
  • 226
  • 227
  • 228
  • 229
  • 230
  • 231
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.